Triapine Added to Cisplatin and Radiation for Cervical/Vaginal Cancer: Phase III ResultsCould a new drug boost survival for women with advanced cervical and vaginal cancers?

Status: ACTIVE_NOT_RECRUITING | Phase: PHASE3 Condition(s): Advanced Vaginal Adenocarcinoma, Advanced Vaginal Adenosquamous Carcinoma, Advanced Vaginal Squamous Cell Carcinoma, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma Intervention(s): Brachytherapy (RADIATION), Cisplatin (DRUG), External Beam Radiation Therapy (RADIATION), Intensity-Modulated Radiation Therapy (RADIATION), Laboratory Biomarker Analysis (OTHER) This randomized phase III trial studies radiation therapy and cisplatin with triapine to see how well they work compared to the standard radiation therapy and cisplatin alone in treating patients with newly diagnosed stage IB2, II, or IIIB-IVA cervical cancer or stage II-IVA vaginal cancer. Radiation therapy uses high energy protons to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether radiation therapy and cisplatin are more effective with triapine in treating cervical or vaginal cancer. Detailed: PRIMARY OBJECTIVE: I. To evaluate the efficacy of the experimental regimen of triapine (3AP), cisplatin, and radiation to increase overall survival relative to the standard/control regimen of cisplatin and radiation in women with uterine cervix or vaginal cancer. SECONDARY OBJECTIVE: I. To determine the relative progression-free survival impact of triapine-cisplatin radio-chemotherapy and cisplatin radio-chemotherapy. TERTIARY OBJECTIVES: I. To evaluate incidence and severity of hematologic and gastrointestinal (GI) adverse events by radiation modality; image guided intensity modulated radiation therapy (IG-IMRT) versus conventional pelvic radiotherapy. (05/30/2017) II. To summarize and compare differences in acute adverse events (Common Terminology Criteria for Adverse Events \[CTCAE Primary Outcome(s): Overall Survival (OS) Rate at 3 Years Enrollment: 450 (ACTUAL) Lead Sponsor: National Cancer Institute (NCI) Start: 2016-05-10 | Primary Completion: 2023-01-26 Results posted: 2024-01-05